{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:24:12Z","timestamp":1791231852468,"version":"4.1.0"},"reference-count":72,"publisher":"Society for Neuroscience","issue":"10","license":[{"start":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T00:00:00Z","timestamp":1694131200000},"content-version":"vor","delay-in-days":226,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000093","name":"HHS | NIH | Center for Information Technology","doi-asserted-by":"publisher","award":["AG050431"],"award-info":[{"award-number":["AG050431"]}],"id":[{"id":"10.13039\/100000093","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000093","name":"HHS | NIH | Center for Information Technology","doi-asserted-by":"publisher","award":["AT010980"],"award-info":[{"award-number":["AT010980"]}],"id":[{"id":"10.13039\/100000093","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["1IK6 BX004982"],"award-info":[{"award-number":["1IK6 BX004982"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Neurosci."],"published-print":{"date-parts":[[2023,3,8]]},"abstract":"<jats:p>Juvenile neuronal ceroid lipofuscinosis (JNCL) is a fatal inherited neurodegenerative disease of children that occurs because of defective function of the lysosomal membrane glycoprotein CLN3. JNCL features glial activation and accumulation of autofluorescent storage material containing subunit c of mitochondrial ATP synthase (SCMAS), ultimately resulting into neuronal loss. Until now, no effective therapy is available for JNCL. This study underlines the possible therapeutic importance of gemfibrozil, an activator of peroxisome proliferator-activated receptor \u03b1 (PPAR\u03b1) and a lipid-lowering drug approved by the Food and Drug Administration in an animal model of JNCL. Oral gemfibrozil treatment reduced microglial and astroglial activation, attenuated neuroinflammation, restored the level of transcription factor EB (TFEB; the master regulator of lysosomal biogenesis), and decreased the accumulation of storage material SCMAS in somatosensory barrel field (SBF) cortex of Cln3<jats:sup>\u0394ex7\/8<\/jats:sup>(Cln3\u0394JNCL) mice of both sexes. Accordingly, gemfibrozil treatment also improved locomotor activities of Cln3\u0394JNCL mice. While investigating the mechanism, we found marked loss of PPAR\u03b1 in the SBF cortex of Cln3\u0394JNCL mice, which increased after gemfibrozil treatment. Oral gemfibrozil also stimulated the recruitment of PPAR\u03b1 to the<jats:italic>Tfeb<\/jats:italic>gene promoter<jats:italic>in vivo<\/jats:italic>in the SBF cortex of Cln3\u0394JNCL mice, indicating increased transcription of<jats:italic>Tfeb<\/jats:italic>in the CNS by gemfibrozil treatment via PPAR\u03b1. Moreover, disease pathologies aggravated in Cln3\u0394JNCL mice lacking PPAR\u03b1 (Cln3\u0394JNCL<jats:sup>\u0394PPAR\u03b1<\/jats:sup>) and gemfibrozil remained unable to decrease SCMAS accumulation, reduce glial activation, and improve locomotor performance of Cln3\u0394JNCL<jats:sup>\u0394PPAR\u03b1<\/jats:sup>mice. These results suggest that activation of PPAR\u03b1 may be beneficial for JNCL and that gemfibrozil may be repurposed for the treatment of this incurable disease.<\/jats:p><jats:p><jats:bold>SIGNIFICANCE STATEMENT<\/jats:bold>Despite intense investigations, no effective therapy is available for JNCL, an incurable inherited lysosomal storage disorder. Here, we delineate that oral administration of gemfibrozil, a lipid-lowering drug, decreases glial inflammation, normalizes and\/or upregulates TFEB, and reduces accumulation of autofluorescent storage material in SBF cortex to improve locomotor activities in Cln3<jats:sup>\u0394ex7\/8<\/jats:sup>(Cln3\u0394JNCL) mice. Aggravation of disease pathology in Cln3\u0394JNCL mice lacking PPAR\u03b1 (Cln3\u0394JNCL<jats:sup>\u0394PPAR\u03b1<\/jats:sup>) and inability of gemfibrozil to decrease SCMAS accumulation, reduce glial activation, and improve locomotor performance of Cln3\u0394JNCL<jats:sup>\u0394PPAR\u03b1<\/jats:sup>mice delineates an important role of PPAR\u03b1 in this process. These studies highlight a new property of gemfibrozil and indicate its possible therapeutic use in JNCL patients.<\/jats:p>","DOI":"10.1523\/jneurosci.2447-21.2023","type":"journal-article","created":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T18:50:28Z","timestamp":1674672628000},"page":"1814-1829","source":"Crossref","is-referenced-by-count":20,"title":["Activation of PPAR\u03b1 Exhibits Therapeutic Efficacy in a Mouse Model of Juvenile Neuronal Ceroid Lipofuscinosis"],"prefix":"10.1523","volume":"43","author":[{"given":"Malabendu","family":"Jana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debashis","family":"Dutta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jit","family":"Poddar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6048-9598","authenticated-orcid":false,"given":"Kalipada","family":"Pahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"393","published-online":{"date-parts":[[2023,1,25]]},"reference":[{"key":"2023050205300708000_43.10.1814.1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-50726-8"},{"key":"2023050205300708000_43.10.1814.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2009.07.001"},{"key":"2023050205300708000_43.10.1814.3","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.3390\/cells9051204","article-title":"The transcription factor EB reduces the intraneuronal accumulation of the beta-secretase-derived APP fragment C99 in cellular and mouse Alzheimer's disease models","volume":"9","author":"Becot","year":"2020","journal-title":"Cells"},{"key":"2023050205300708000_43.10.1814.4","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.1635-16.2016"},{"key":"2023050205300708000_43.10.1814.5","doi-asserted-by":"publisher","DOI":"10.1007\/s12031-017-0962-5"},{"key":"2023050205300708000_43.10.1814.6","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M602180200"},{"key":"2023050205300708000_43.10.1814.7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0017118"},{"key":"2023050205300708000_43.10.1814.8","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1038\/s41591-020-0986-1","article-title":"Therapeutic efficacy of antisense oligonucleotides in mouse models of CLN3 Batten disease","volume":"26","author":"Centa","year":"2020","journal-title":"Nat Med"},{"key":"2023050205300708000_43.10.1814.9","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/jnc.14813","article-title":"Aspirin up-regulates suppressor of cytokine signaling 3 in glial cells via PPAR\u03b1","volume":"151","author":"Chakrabarti","year":"2019","journal-title":"J Neurochem"},{"key":"2023050205300708000_43.10.1814.10","doi-asserted-by":"crossref","first-page":"647","DOI":"10.3233\/ADR-210026","article-title":"Upregulation of IL-1 receptor antagonist by aspirin in glial cells via peroxisome proliferator-activated receptor-alpha","volume":"5","author":"Chakrabarti","year":"2021","journal-title":"J Alzheimers Dis Rep"},{"key":"2023050205300708000_43.10.1814.11","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M116.714824"},{"key":"2023050205300708000_43.10.1814.12","doi-asserted-by":"publisher","DOI":"10.3233\/ADR-190104"},{"key":"2023050205300708000_43.10.1814.13","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.0054-18.2018"},{"key":"2023050205300708000_43.10.1814.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2015.05.014"},{"key":"2023050205300708000_43.10.1814.15","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1102624"},{"key":"2023050205300708000_43.10.1814.16","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1504890112"},{"key":"2023050205300708000_43.10.1814.17","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/11.22.2709"},{"key":"2023050205300708000_43.10.1814.18","doi-asserted-by":"publisher","DOI":"10.1242\/dmm.033597"},{"key":"2023050205300708000_43.10.1814.19","doi-asserted-by":"publisher","DOI":"10.1124\/mol.106.033787"},{"key":"2023050205300708000_43.10.1814.20","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25767-1"},{"key":"2023050205300708000_43.10.1814.21","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M112.346932"},{"key":"2023050205300708000_43.10.1814.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2015.11.011"},{"key":"2023050205300708000_43.10.1814.23","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M112.365148"},{"key":"2023050205300708000_43.10.1814.24","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M114.610659"},{"key":"2023050205300708000_43.10.1814.25","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/jnc.13987","article-title":"Gemfibrozil, food and drug administration-approved lipid-lowering drug, increases longevity in mouse model of late infantile neuronal ceroid lipofuscinosis","volume":"141","author":"Ghosh","year":"2017","journal-title":"J Neurochem"},{"key":"2023050205300708000_43.10.1814.26","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.3018-19.2021"},{"key":"2023050205300708000_43.10.1814.27","doi-asserted-by":"publisher","DOI":"10.1006\/mgme.1999.2828"},{"key":"2023050205300708000_43.10.1814.28","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1016\/j.ymthe.2017.04.021","article-title":"Fingolimod and teriflunomide attenuate neurodegeneration in mouse models of neuronal ceroid lipofuscinosis","volume":"25","author":"Groh","year":"2017","journal-title":"Mol Ther"},{"key":"2023050205300708000_43.10.1814.29","doi-asserted-by":"publisher","DOI":"10.1053\/eipn.2000.0464"},{"key":"2023050205300708000_43.10.1814.30","doi-asserted-by":"publisher","DOI":"10.1007\/s11064-012-0781-6"},{"key":"2023050205300708000_43.10.1814.31","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.179.6.4142"},{"key":"2023050205300708000_43.10.1814.32","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.10.7254"},{"key":"2023050205300708000_43.10.1814.33","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M112.398552"},{"key":"2023050205300708000_43.10.1814.34","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-019-0138-8"},{"key":"2023050205300708000_43.10.1814.35","first-page":"2375","article-title":"Immunochemical localization of the Batten disease (CLN3) protein in retina","volume":"38","author":"Katz","year":"1997","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2023050205300708000_43.10.1814.36","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s13023-017-0663-8","article-title":"Safety and potential efficacy of gemfibrozil as a supportive treatment for children with late infantile neuronal ceroid lipofuscinosis and other lipid storage disorders","volume":"12","author":"Kim","year":"2017","journal-title":"Orphanet J Rare Dis"},{"key":"2023050205300708000_43.10.1814.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2007.09.012"},{"key":"2023050205300708000_43.10.1814.38","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2006.05.007"},{"key":"2023050205300708000_43.10.1814.39","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s40478-018-0575-4","article-title":"Compromised astrocyte function and survival negatively impact neurons in infantile neuronal ceroid lipofuscinosis","volume":"6","author":"Lange","year":"2018","journal-title":"Acta Neuropathol Commun"},{"key":"2023050205300708000_43.10.1814.40","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.172.9.5790"},{"key":"2023050205300708000_43.10.1814.41","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12615"},{"key":"2023050205300708000_43.10.1814.42","doi-asserted-by":"publisher","DOI":"10.1016\/j.tins.2016.02.002"},{"key":"2023050205300708000_43.10.1814.43","doi-asserted-by":"crossref","first-page":"e859","DOI":"10.1002\/mgg3.859","article-title":"The CLN3 gene and protein: what we know","volume":"7","author":"Mirza","year":"2019","journal-title":"Mol Genet Genomic Med"},{"key":"2023050205300708000_43.10.1814.44","doi-asserted-by":"publisher","DOI":"10.1006\/nbdi.1999.0267"},{"key":"2023050205300708000_43.10.1814.45","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2015.05.011"},{"key":"2023050205300708000_43.10.1814.46","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.146365"},{"key":"2023050205300708000_43.10.1814.47","doi-asserted-by":"publisher","DOI":"10.1016\/S0891-5849(97)00137-8"},{"key":"2023050205300708000_43.10.1814.48","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M200250200"},{"key":"2023050205300708000_43.10.1814.49","doi-asserted-by":"publisher","DOI":"10.1007\/s11481-020-09979-8"},{"key":"2023050205300708000_43.10.1814.50","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2100144"},{"key":"2023050205300708000_43.10.1814.51","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2015.06.014"},{"key":"2023050205300708000_43.10.1814.52","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s40478-017-0476-y","article-title":"Glial cells are functionally impaired in juvenile neuronal ceroid lipofuscinosis and detrimental to neurons","volume":"5","author":"Parviainen","year":"2017","journal-title":"Acta Neuropathol Commun"},{"key":"2023050205300708000_43.10.1814.53","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1802021115"},{"key":"2023050205300708000_43.10.1814.54","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s11481-019-09855-0","article-title":"Cinnamon and its metabolite protect the nigrostriatum in a mouse model of Parkinson's disease via astrocytic GDNF","volume":"14","author":"Patel","year":"2019","journal-title":"J Neuroimmune Pharmacol"},{"key":"2023050205300708000_43.10.1814.55","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.3390\/cells8121531","article-title":"An autophagy modifier screen identifies small molecules capable of reducing autophagosome accumulation in a model of CLN3-mediated neurodegeneration","volume":"8","author":"Petcherski","year":"2019","journal-title":"Cells"},{"key":"2023050205300708000_43.10.1814.56","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.2007.04920.x"},{"key":"2023050205300708000_43.10.1814.57","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2005.05.018"},{"key":"2023050205300708000_43.10.1814.58","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1007\/s11481-020-09955-2","article-title":"Reduction of Lewy body pathology by oral cinnamon","volume":"16","author":"Raha","year":"2020","journal-title":"J Neuroimmune Pharmacol"},{"key":"2023050205300708000_43.10.1814.59","doi-asserted-by":"crossref","first-page":"eabg4747","DOI":"10.1126\/scisignal.abg4747","article-title":"Activation of PPAR\u03b1 enhances astroglial uptake and degradation of \u03b2-amyloid","volume":"14","author":"Raha","year":"2021","journal-title":"Sci Signal"},{"key":"2023050205300708000_43.10.1814.60","doi-asserted-by":"publisher","DOI":"10.1172\/JCI96209"},{"key":"2023050205300708000_43.10.1814.61","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1080\/21678707.2019.1684258","article-title":"Advances in the treatment of neuronal ceroid lipofuscinosis","volume":"7","author":"Rosenberg","year":"2019","journal-title":"Expert Opin Orphan Drugs"},{"key":"2023050205300708000_43.10.1814.62","doi-asserted-by":"publisher","DOI":"10.1080\/08923970902785253"},{"key":"2023050205300708000_43.10.1814.63","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M600236200"},{"key":"2023050205300708000_43.10.1814.64","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M702899200"},{"key":"2023050205300708000_43.10.1814.65","doi-asserted-by":"publisher","DOI":"10.1089\/ars.2006.8.929"},{"key":"2023050205300708000_43.10.1814.66","doi-asserted-by":"crossref","first-page":"8055","DOI":"10.3390\/ijms21218055","article-title":"Current insights in elucidation of possible molecular mechanisms of the juvenile form of Batten disease","volume":"21","author":"Shematorova","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2023050205300708000_43.10.1814.67","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s40265-020-01440-7","article-title":"Neuronal ceroid lipofuscinosis: potential for targeted therapy","volume":"81","author":"Specchio","year":"2021","journal-title":"Drugs"},{"key":"2023050205300708000_43.10.1814.68","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2018.11.39"},{"key":"2023050205300708000_43.10.1814.69","doi-asserted-by":"publisher","DOI":"10.1111\/j.1750-3639.2004.tb00077.x"},{"key":"2023050205300708000_43.10.1814.70","doi-asserted-by":"publisher","DOI":"10.12968\/bjon.2014.23.13.704"},{"key":"2023050205300708000_43.10.1814.71","doi-asserted-by":"crossref","unstructured":"Wang H , Wang R , Carrera I , Xu S , Lakshmana MK (2016) TFEB overexpression in the P301S model of tauopathy mitigates increased PHF1 levels and lipofuscin puncta and rescues memory deficits. eNeuro 3:ENEURO.0042-16.2016. https:\/\/doi.org\/10.1523\/ENEURO.0042-16.2016","DOI":"10.1523\/ENEURO.0042-16.2016"},{"key":"2023050205300708000_43.10.1814.72","doi-asserted-by":"publisher","DOI":"10.1111\/jnc.12385"}],"container-title":["The Journal of Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1523\/JNEUROSCI.2447-21.2023","content-type":"unspecified","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1523\/JNEUROSCI.2447-21.2023","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T12:31:41Z","timestamp":1683030701000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jneurosci.org\/lookup\/doi\/10.1523\/JNEUROSCI.2447-21.2023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,25]]},"references-count":72,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,3,8]]},"published-print":{"date-parts":[[2023,3,8]]}},"alternative-id":["10.1523\/JNEUROSCI.2447-21.2023"],"URL":"https:\/\/doi.org\/10.1523\/jneurosci.2447-21.2023","relation":{},"ISSN":["0270-6474","1529-2401"],"issn-type":[{"value":"0270-6474","type":"print"},{"value":"1529-2401","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,25]]}}}